N (%) (n=27) | ||
Age | Median (years; range) | 55 (38–74) |
Sex | Male | 17 (63) |
Female | 10 (37) | |
ECOG PS | 0 | 10 (37) |
1 | 14 (52) | |
2 | 3 (11) | |
Primary histopathologic diagnosis | WHO Grade IV | 22 (81) |
WHO Grade III | 4 (15) | |
WHO Grade II | 1 (4) | |
IDH1/2 mutation status | Mutant | 2 (7) |
Wild-type | 25 (93) | |
MGMT-promotor methylation status | Methylated | 7 (26) |
Unmethylated | 13 (48) | |
Unknown | 7 (26) | |
1 p/19q codeletion | Yes | 0 (0) |
No | 8 (30) | |
Unknown | 19 (70) | |
Prior surgical intervention | Resection | 27 (100) |
Biopsy | 0 (0) | |
Prior therapy for primary diagnosis of glioma | Surgery+concomitant RT/TMZ+adjuvant TMZ | 23 (85) |
Surgery only | 2 (7) | |
Surgery+RT | 2 (7) | |
Therapy for prior recurrent disease | Surgery only | 2 (7) |
Surgery+RT+TMZ | 2 (7) | |
Surgery+RT | 1 (4) | |
Surgery+TMZ | 1 (4) | |
Surgery+TMZ+lomustine | 1 (4) | |
Surgery+irinotecan | 1 (4) | |
RT+TMZ | 1 (4) | |
Median of prior systemic therapies | 3 (1–4) |
1p/19q codeletion: deletion of the short arm of chromosome 1 and long arm of chromosome 19.
ECOG, Eastern cooperative oncology group; IDH1/2, isocitrate dehydrogenase 1/2; MGMT, methylated O6-methylguanine-DNA methyltransferase; RT, radiotherapy; TMZ, temozolomide.